Smoking cessation in chronic obstructive pulmonary disease.

[1]  J. Connett,et al.  Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. , 2009, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[2]  Swu-Jane Lin,et al.  Systematic review and meta-analysis of combination therapy for smoking cessation. , 2008, Journal of the American Pharmacists Association : JAPhA.

[3]  B. Kuehn.  Updated US smoking cessation guideline advises counseling, combining therapies. , 2008, JAMA.

[4]  T. Greenhalgh,et al.  Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial , 2008, BMJ : British Medical Journal.

[5]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[6]  R. Perera,et al.  A systematic review of interventions for smokers who contact quitlines , 2007, Tobacco Control.

[7]  K. Luker,et al.  Smoking cessation interventions in chronic obstructive pulmonary disease and the role of the family: a systematic literature review. , 2007, Journal of advanced nursing.

[8]  H. Hamilton,et al.  Improving in-office discussion of chronic obstructive pulmonary disease: results and recommendations from an in-office linguistic study in chronic obstructive pulmonary disease. , 2007, The American journal of medicine.

[9]  E. Seydel,et al.  Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. , 2007, Patient education and counseling.

[10]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[11]  R. Schapira,et al.  The outpatient diagnosis and management of chronic obstructive pulmonary disease , 2007, Journal of General Internal Medicine.

[12]  Matthew J Carpenter,et al.  Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. , 2006, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[13]  Jason Gong,et al.  Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial , 2006 .

[14]  David Gonzales,et al.  Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial , 2006 .

[15]  D. Górecka,et al.  Smokers with airway obstruction are more likely to quit smoking , 2006, Thorax.

[16]  Ian Wilson,et al.  Depression in the patient with COPD , 2006, International journal of chronic obstructive pulmonary disease.

[17]  P. Jakobsson,et al.  The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD , 2006, Scandinavian journal of primary health care.

[18]  P. Tønnesen,et al.  Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. , 2006, Chest.

[19]  F. Tingley,et al.  3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation , 2005 .

[20]  D. Postma,et al.  High cessation rates of cigarette smoking in subjects with and without COPD. , 2005, Chest.

[21]  E. Wouters,et al.  Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. , 2005, Archives of internal medicine.

[22]  Fernando Holguin,et al.  Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. , 2005, Chest.

[23]  J. Changeux,et al.  Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors , 2005, Nature.

[24]  P. Paré,et al.  Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis , 2005, Thorax.

[25]  J. Connett,et al.  Smoking reduction and the rate of decline in FEV1: results from the Lung Health Study , 2005, European Respiratory Journal.

[26]  John Connett,et al.  The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005, Annals of Internal Medicine.

[27]  M. Walter,et al.  Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients , 1995, Psychopharmacology.

[28]  D. Mant,et al.  Nicotine replacement therapy for smoking cessation. , 2005, The Cochrane database of systematic reviews.

[29]  D. Mannino,et al.  Global Initiative on Obstructive Lung Diseases (GOLD) classification of COPD and incident lung cancer: findings from a cohort study , 2004 .

[30]  C. P. Schayck,et al.  The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. , 2004, Respiratory medicine.

[31]  J. Connett,et al.  Smoking reduction in the Lung Health Study. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[32]  Office on Smoking.  The Health Consequences of Smoking: A Report of the Surgeon General , 2004 .

[33]  L. Epstein,et al.  Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. , 2003, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[34]  M. Morgan,et al.  Chronic obstructive pulmonary disease • 8: Non-pharmacological management of COPD , 2003, Thorax.

[35]  C. V. van Schayck,et al.  Smoking cessation for chronic obstructive pulmonary disease. , 2003, The Cochrane database of systematic reviews.

[36]  J. Cryan,et al.  Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat , 2003, Psychopharmacology.

[37]  E. Arias,et al.  Deaths: preliminary data for 2011. , 2012, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[38]  D. Sin,et al.  The risk of osteoporosis in Caucasian men and women with obstructive airways disease. , 2003, The American journal of medicine.

[39]  D. DeMeo,et al.  The genetics of chronic obstructive pulmonary disease , 2001, Seminars in respiratory and critical care medicine.

[40]  M. Decramer,et al.  Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey , 2002, European Respiratory Journal.

[41]  C. Rand,et al.  Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. , 2002, Preventive medicine.

[42]  John E Connett,et al.  Smoking and lung function of Lung Health Study participants after 11 years. , 2002, American journal of respiratory and critical care medicine.

[43]  D. Mannino,et al.  Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. , 2002, Morbidity and mortality weekly report. Surveillance summaries.

[44]  D. Mannino.  COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. , 2002, Chest.

[45]  L. Newman,et al.  Genetic and environmental modulation of chronic obstructive pulmonary disease. , 2001, Respiration physiology.

[46]  N. Pride.  Smoking cessation: effects on symptoms, spirometry and future trends in COPD. , 2001, Thorax.

[47]  N. Anthonisen,et al.  Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. , 2001, American journal of respiratory and critical care medicine.

[48]  P. Anderson,et al.  Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial , 2001, The Lancet.

[49]  M. Miravitlles,et al.  Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. , 2001, Chest.

[50]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[51]  N. Anthonisen,et al.  Characteristics of participants who stop smoking and sustain abstinence for 1 and 5 years in the Lung Health Study. , 2000, Preventive medicine.

[52]  T. Petty,et al.  Scope of the COPD problem in North America: early studies of prevalence and NHANES III data: basis for early identification and intervention. , 2000, Chest.

[53]  W. Bailey,et al.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. , 2000, American journal of respiratory and critical care medicine.

[54]  Aker,et al.  A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. , 1999, The New England journal of medicine.

[55]  D. Mannino,et al.  Worldwide epidemiology of chronic obstructive pulmonary disease. , 1999, Current opinion in pulmonary medicine.

[56]  C. Rand,et al.  Effect of weight gain on pulmonary function after smoking cessation in the Lung Health Study. , 1998, American journal of respiratory and critical care medicine.

[57]  N. Anthonisen,et al.  Effects of multiple attempts to quit smoking and relapses to smoking on pulmonary function. Lung Health Study Research Group. , 1998, Journal of clinical epidemiology.

[58]  J. Connett,et al.  Early and late weight gain following smoking cessation in the Lung Health Study. , 1998, American journal of epidemiology.

[59]  A. Blum,et al.  Tobacco Use Among U.S. Racial/Ethnic Minority Groups-African Americans, American Indians and Alaska Natives, Asian Americans and Pacific Islanders, and Hispanics: A Report of the Surgeon General , 1998 .

[60]  I. Ockene,et al.  Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. , 1997, Circulation.

[61]  W. Bailey,et al.  Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. , 1996, Chest.

[62]  S. Holgate,et al.  Do lower respiratory tract infections in early childhood cause chronic obstructive pulmonary disease , 1995 .

[63]  J. J. Johnston,et al.  Social support for smoking cessation and abstinence: the Lung Health Study. Lung Health Study Research Group. , 1995, Addictive behaviors.

[64]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[65]  C. Rand,et al.  Weight gain as a function of smoking cessation and 2-mg nicotine gum use among middle-aged smokers with mild lung impairment in the first 2 years of the Lung Health Study. , 1994, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[66]  G. O'Connor,et al.  The relation of airways responsiveness and atopy to the development of chronic obstructive lung disease. , 1988, Epidemiologic reviews.

[67]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.

[68]  M. Gorman,et al.  Alkaloids of Vinca rosea Linn. (Catharanthus roseus G. Don.). V. Preparation and characterization of alkaloids. , 2006, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.